Home
About
Our Pipeline
FDA Status
Our Team
Market Size
Equity Capital
Contact
Partnerships
Scientists
Synthetic Vs. Herbal
Antimicrobial Resistance
Why Stramsen
News
News Archives
Donations
Invest Now
More
Stramsen Biotech Inc. Announced Eleven New Natural Plant-based Drug / Medicine Candidates During its Board Members' Meeting (prnewswire.com)
Stramsen Biotech, Inc Announces $10 Million Series Financing Round at $807 Million Valuation (prnewswire.com)
Stramsen Biotech Joins Elite Class of Unicorns at $6.5 Billion Valuation and a Potential Reverse Merger Deal (prnewswire.com)
Stramsen Biotech Inc. Announced Military Veteran Mr. Chris White -(MBA) as The New President and Chief Financial Officer (prnewswire.com)
Stramsen Biotech Announces Partnership with Nasdaq Private Market (NPM) | FirstWord Pharma
Stramsen Biotech Inc. Announced Mr. Joe Meuth as The Chairman of the Board of Directors and Mr. Peter Olsen as President and CFO (prnewswire.com)
Stramsen Biotech Inc. Appoints Dr. Kefas (Ph.D.) and Christopher Ramirez as Co-CEOs for The New Biotech Company (prnewswire.com)
Stramsen Biotech, Inc Announces Six Drug / Medicine Candidates Currently in Early-Stage Clinical Trials (prnewswire.com)
Stramsen Biotech Announces Partnership with Nasdaq Private Market (NPM) | Prnewswire | starlocalmedia.com
Stramsen Biotech is Valued at $19 Billion, Seeks Investment Banks and Law Firms, and Reserves SBRX as Its Trading Symbol
Stramsen Biotech Thanks the FDA for Their Review and Positive Feedback on Pre IND Application for SBX-1977 Wound Care Medicine
Stramsen Biotech Submits Pre-IND Package to FDA for SBX 1977 Wound Care Medicine, Requests Pre-IND Meeting and Phase 2 Trial
Stramsen Biotech Inc. Announced $25 Million Funding Commitment from GEM Global Yield LLC SCS ("GEM")